XML 52 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 9 - Segment Information
 9 Months Ended
Dec. 31, 2014
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]

Note 9 - Segment Information


We have three reporting segments: Biological Indicators, Instruments and Continuous Monitoring. The following tables set forth our segment information (in thousands):


   

Three Months Ended December 31, 2014

 
   

Biological

Indicators

   

Instruments

   

Continuous

Monitoring

   

Total

 

Revenues

  $ 6,964     $ 8,216     $ 2,650     $ 17,830  
                                 

Gross profit

  $ 4,194     $ 5,412     $ 1,446     $ 11,052  

Selling expenses

    365       919       488       1,772  
    $ 3,829     $ 4,493     $ 958       9,280  

Reconciling items (1)

                            (5,567 )

Earnings before income taxes

                          $ 3,713  

   

Three Months Ended December 31, 2013

 
   

Biological

Indicators

   

Instruments

   

Continuous

Monitoring

   

Total

 

Revenues

  $ 5,317     $ 6,438     $ 1,361     $ 13,116  
                                 

Gross profit

  $ 2,976     $ 4,137     $ 593     $ 7,706  

Selling expenses

    404       1,047       144       1,595  
    $ 2,572     $ 3,090     $ 449       6,111  

Reconciling items (1)

                            (3,384 )

Earnings before income taxes

                          $ 2,727  

   

Nine Months Ended December 31, 2014

 
   

Biological

Indicators

   

Instruments

   

Continuous

Monitoring

   

Total

 

Revenues

  $ 19,822     $ 24,966     $ 7,982     $ 52,770  
                                 

Gross profit

  $ 12,029     $ 15,794     $ 4,057     $ 31,880  

Selling expenses

    766       3,093       1,318       5,177  
    $ 11,263     $ 12,701     $ 2,739       26,703  

Reconciling items (1)

                            (15,354 )

Earnings before income taxes

                          $ 11,349  

   

Nine Months Ended December 31, 2013

 
   

Biological

Indicators

   

Instruments

   

Continuous

Monitoring

   

Total

 

Revenues

  $ 16,181     $ 19,468     $ 1,361     $ 37,010  
                                 

Gross profit

  $ 9,019     $ 12,491     $ 593     $ 22,103  

Selling expenses

    1,350       2,603       144       4,097  
    $ 7,669     $ 9,888     $ 449       18,006  

Reconciling items (1)

                            (9,326 )

Earnings before income taxes

                          $ 8,680  

(1) Reconciling items include general and administrative, research and development, and other expenses.


   

December 31, 2014

   

March 31, 2014

 

Total assets

               

Biological Indicators

  $ 25,921     $ 22,771  

Instruments

    54,308       36,797  

Continuous Monitoring

    31,086       28,578  

Corporate and administrative

    4,863       9,383  
    $ 116,178     $ 97,529  

All long-lived assets are located in the United States except for $3,269,000 which are associated with our subsidiary which is located in Chassieu, France.


Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows (in thousands):


   

Three Months Ended December 31,

   

Nine Months Ended December 31,

 
   

2014

   

2013

   

2014

   

2013

 

Net revenues from unaffiliated customers:

                               

United States

  $ 11,423     $ 7,054     $ 29,612     $ 20,877  

Foreign

    6,407       6,062       23,158       16,133  
    $ 17,830     $ 13,116     $ 52,770     $ 37,010  

No foreign country exceeds 10% of total revenues.